Therapy News and Research

RSS

HDAC6 enzyme could be possible target for therapies against Alzheimer's

Scientists from the DZNE sites in G-ttingen and Bonn, the UMG as well as from the US participated in this basic research project on Alzheimer's disease. The study is published in "EMBO Molecular Medicine".

30 Nov 2012

Air quality in cities linked to inflammatory risk in diabetes

Exposure to traffic-related air pollutants is associated with a rapid increase in systemic inflammation in patients with diabetes, report Indian researchers.

30 Nov 2012

Infrared therapy could help prevent anal cancer in HIV-positive population

Infrared coagulopathy treatment of a potential precursor of anal cancer is effective and warrants further study as a way to reduce anal cancer incidence and mortality among HIV-infected people, report researchers.

30 Nov 2012

Orthopedic surgery relieves breast cancer metastases

Results of a review demonstrate the key role orthopedic surgery can play in the care of breast cancer patients with bone metastases.

30 Nov 2012

Lewy pathology out of favor as Parkinson’s culprit

Neurodegeneration and cellular dysfunction may precede the appearance of Lewy bodies in the substantia nigra, shows research that challenges the role of Lewy pathology in Parkinson’s disease.

30 Nov 2012

Combination of chemotherapy and selumetinib shows promise against NSCLC

A new study by an international team of investigators led by Dana-Farber Cancer Institute scientists is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer.

30 Nov 2012

VAC-3S immunotherapeutic vaccine for HIV completes first clinical development phase

InnaVirVax, a biopharmaceutical company specialized in research and development on therapeutic and diagnostic solutions for diseases linked to immune dysregulation, has just announced successful completion of the first clinical development phase for VAC-3S immunotherapy in the treatment of HIV infections.

30 Nov 2012

GM1 ganglioside effectively treats patients with Parkinson's disease

Treating Parkinson's disease patients with the experimental drug GM1 ganglioside improved symptoms and slowed their progression during a two and a half-year trial, Thomas Jefferson University researchers report in a new study published online November 28 in the Journal of the Neurological Sciences.

30 Nov 2012

Study: Controversial treatment for autism spectrum disorder may be harmful

A controversial treatment for autism spectrum disorder (ASD) is not only ineffective but may be harmful, according to a study conducted by Baylor University researchers.

30 Nov 2012

JQ1 cancer drug may be useful in purging latent HIV infection

Breakthrough drugs have made it possible for people to live with HIV longer than ever before, but more work must be done to actually cure the disease. One of the challenges researchers face involves fully eradicating the virus when it is latent in the body.

30 Nov 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

Boehringer Ingelheim announces new data from volasertib Phase I/II leukemia study

Boehringer Ingelheim today announced that new data evaluating volasertib, an investigational polo-like kinase (Plk) inhibitor, will be presented at the 54th American Society of Hematology (ASH) annual meeting taking place December 8-11 in Atlanta, Ga.

30 Nov 2012

U.K. NICE issues final draft guidance on Alimera Sciences’ ILUVIEN

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has issued final draft guidance indicating that ILUVIEN is not recommended for the treatment of chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.

30 Nov 2012